New study tracks hemophilia a risks in mothers and babies
NCT ID NCT07414511
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 500 mother-child pairs where the mother has a severe hemophilia A gene. It aims to understand bleeding risks during pregnancy and childbirth for mothers, and how children develop antibodies to factor VIII treatment. By observing families over time, researchers hope to identify genetic and environmental factors that influence these outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could improve understanding of bleeding risks during pregnancy for mothers with hemophilia A and how children develop antibodies to treatment.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly lead to new therapies. Results may take years and may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOIMMUNIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Washington
RECRUITINGSeattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a class tame pregnancy stress at the genetic level?
- A nationwide test: do home visits build healthier families?
- Can a simple calcium tablet help prevent postpartum bleeding?
- Can AI read ultrasound sweeps to tell Baby's position?
- Could a smart ring unlock secrets of pregnancy health?